166 related articles for article (PubMed ID: 31473468)
21. Survival of myeloma patients following the introduction of thalidomide as a second-line therapy: a retrospective study at a single New Zealand centre.
Fernyhough LJ; Hock BD; Taylor J; Pearson J; Ganly P
Intern Med J; 2013 Feb; 43(2):130-7. PubMed ID: 22530659
[TBL] [Abstract][Full Text] [Related]
22. [The Veneto Region's Registry of Dialysis and Transplantation: 2006-2007 report].
Antonucci F; Camerin E; Feriani M; Nordio M; Piccoli A; Rossi B; Tessitore N
G Ital Nefrol; 2009; 26 Suppl 48():S5-56. PubMed ID: 19927265
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis.
Liu WN; Chang CF; Chung CH; Chien WC; Huang TC; Wu YY; Ho CL; Chen JH
PLoS One; 2019; 14(9):e0222522. PubMed ID: 31527921
[TBL] [Abstract][Full Text] [Related]
24. Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort.
Chen Y; Lairson DR; Chan W; Du XL
Med Oncol; 2017 Sep; 34(9):153. PubMed ID: 28776319
[TBL] [Abstract][Full Text] [Related]
25. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
26. Multiple myeloma: practice patterns across Europe.
Raab MS; Cavo M; Delforge M; Driessen C; Fink L; Flinois A; Gonzalez-McQuire S; Safaei R; Karlin L; Mateos MV; Schoen P; Yong K
Br J Haematol; 2016 Oct; 175(1):66-76. PubMed ID: 27291397
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life.
Greil C; Engelhardt M; Ihorst G; Schoeller K; Bertz H; Marks R; Zeiser R; Duyster J; Einsele H; Finke J; Wäsch R
Haematologica; 2019 Feb; 104(2):370-379. PubMed ID: 30237266
[TBL] [Abstract][Full Text] [Related]
28. Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups.
Libby E; Garcia D; Quintana D; Fekrazad MH; Bauman J; Ebaid A; Hromas R; Rabinowitz I; Wiggins C
Leuk Lymphoma; 2014 Dec; 55(12):2850-7. PubMed ID: 24588734
[TBL] [Abstract][Full Text] [Related]
29. Variation in incidence and survival by ethnicity for patients with myeloma in England (2002-2008).
Samy EF; Ross J; Bolton E; Morris EJ; Oliver SE
Leuk Lymphoma; 2015; 56(9):2660-7. PubMed ID: 25651425
[TBL] [Abstract][Full Text] [Related]
30. Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico.
Tarín-Arzaga L; Arredondo-Campos D; Martínez-Pacheco V; Martínez-González O; Ramírez-López A; Gómez-De León A; Gutiérrez-Aguirre CH; Cantú-Rodríguez O; Jaime-Pérez JC; Gómez-Almaguer D
Cancer; 2018 May; 124(9):1946-1953. PubMed ID: 29461639
[TBL] [Abstract][Full Text] [Related]
31. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.
Usmani SZ; Hoering A; Cavo M; Miguel JS; Goldschimdt H; Hajek R; Turesson I; Lahuerta JJ; Attal M; Barlogie B; Lee JH; Kumar S; Lenhoff S; Morgan G; Rajkumar SV; Durie BGM; Moreau P
Blood Cancer J; 2018 Nov; 8(12):123. PubMed ID: 30470751
[TBL] [Abstract][Full Text] [Related]
32. Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.
Mohty M; Cavo M; Fink L; Gonzalez-McQuire S; Leleu H; Mateos MV; Raab MS; Schoen P; Yong K
Eur J Haematol; 2019 Aug; 103(2):107-115. PubMed ID: 31112311
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
34. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Mateos MV; Cavo M; Blade J; Dimopoulos MA; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Krevvata M; Chen Y; Wang J; Kudva A; Ukropec J; Wroblewski S; Qi M; Kobos R; San-Miguel J
Lancet; 2020 Jan; 395(10218):132-141. PubMed ID: 31836199
[TBL] [Abstract][Full Text] [Related]
35. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
36. Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries.
Blimark CH; Vangsted AJ; Klausen TW; Gregersen H; Szabo AG; Hermansen E; Wålinder G; Knut-Bojanowska D; Zang C; Turesson I;
Eur J Haematol; 2022 Feb; 108(2):99-108. PubMed ID: 34514635
[TBL] [Abstract][Full Text] [Related]
37. Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma.
Giaccone L; Evangelista A; Patriarca F; Sorasio R; Pini M; Carnevale-Schianca F; Festuccia M; Brunello L; Zallio F; Maffini E; Omedé P; Bringhen S; Mordini N; Fanin R; Ciccone G; Boccadoro M; Bruno B
Biol Blood Marrow Transplant; 2018 Jan; 24(1):189-193. PubMed ID: 28987930
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Moreau P; Attal M; Hulin C; Arnulf B; Belhadj K; Benboubker L; Béné MC; Broijl A; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Garderet L; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Lenain P; Macro M; Mathiot C; Orsini-Piocelle F; Perrot A; Stoppa AM; van de Donk NW; Wuilleme S; Zweegman S; Kolb B; Touzeau C; Roussel M; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Fermand JP; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Zhuang S; Chiu C; Pei L; de Boer C; Smith E; Deraedt W; Kampfenkel T; Schecter J; Vermeulen J; Avet-Loiseau H; Sonneveld P
Lancet; 2019 Jul; 394(10192):29-38. PubMed ID: 31171419
[TBL] [Abstract][Full Text] [Related]
39. Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry.
Huang TC; Huang SY; Yao M; Lin CY; Hwang WL; Gau JP; Tan TD; Wang PN; Liu YC; Lin SC; Kao RH; Pei SN; Yu MS; Lin HY; Su YC; Chen CC; Li SS; Wu YY
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):471-480. PubMed ID: 30119948
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.
Terpos E; Katodritou E; de la Rubia J; Hungria V; Hulin C; Roussou M; Delforge M; Bries G; Stoppa AM; Aagesen J; Sargin D; Belch A; Ahlberg L; Diels J; Olie RA; Robinson D; Spencer M; Potamianou A; van de Velde H; Dimopoulos MA
Eur J Haematol; 2018 Oct; 101(4):556-565. PubMed ID: 30027641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
